Innovative Footwear Revolution: UGM Students Develop ‘Glucowrap,’ a Smart Sandal System to Detect Diabetic Foot Complications Early

JAKARTA — Type 2 diabetes mellitus is often referred to as a silent threat, creeping into the lives of millions worldwide through metabolic disruption. However, one of its most debilitating and frequently overlooked consequences occurs far from the pancreas: in the lower extremities. Patients with chronic type 2 diabetes frequently suffer from peripheral neuropathy, a form of nerve damage that drastically diminishes sensation in the feet.

Stripped of their normal pain receptors, patients routinely walk on pressure points, experience continuous friction, or sustain minor cuts and abrasions without ever feeling them. Left unattended, these seemingly innocuous injuries escalate rapidly into severe ulcers, infections, and, in worst-case scenarios, lower-limb amputations.

Recognizing this critical healthcare gap, a brilliant multidisciplinary team of students from Universitas Gadjah Mada (UGM) in Yogyakarta, Indonesia, has engineered a cutting-edge technological intervention. Dubbed ‘Glucowrap,’ this breakthrough innovation is a specialized "smart sandal" system designed to continuously and intelligently monitor foot health parameters in real-time, offering early detection of diabetic foot complications before they spiral into critical medical emergencies.

1. Main Facts: The Anatomy of the Glucowrap Innovation

The Glucowrap is not merely a pair of therapeutic shoes; it is a wearable health monitoring ecosystem that bridges podiatry and digital health technology.

At its core, the open-toe sandal design integrates an array of advanced, low-profile sensors engineered to capture continuous biometric data while the user walks. These sensors meticulously track three primary physiological and environmental indicators:

• Plantar Pressure: Identifying abnormal weight distribution and high-friction zones that typically precede blistering or ulceration.
• Skin Temperature: Detecting localized inflammatory responses or early signs of infection hidden beneath the surface.
• Moisture Levels: Monitoring sweat and humidity within the footbed, which can accelerate bacterial proliferation and skin breakdown.

The raw data harvested by these sensors is instantly processed and transmitted to a companion mobile application. Through this app, patients, their family members, and caregivers can monitor foot health status in real time. The software categorizes the risk into three easily understandable tiers: Normal, Mild Risk, and High Risk, empowering users to take proactive corrective action.

Beyond its digital capabilities, the Glucowrap incorporates sophisticated materials science. The internal lining that directly contacts the skin is constructed from bamboo fiber biotextiles treated with chitosan—a natural biopolymer celebrated for its potent antibacterial and wound-healing properties. Furthermore, the sandal features an integrated thermal and low-intensity micro-vibration stimulation system, designed to enhance localized blood circulation and provide therapeutic comfort to the wearer.

2. Chronology: From Concept to Clinical Trials

The journey of the Glucowrap from a theoretical classroom concept to a validated clinical prototype is a testament to rigorous academic research and collaborative innovation.

The Inception (Late 2025 – Early 2026)

The project took shape under the banner of the Student Creativity Program in the field of Artificial Creation (Program Kreativitas Mahasiswa bidang Karsa Cipta or PKM-KC) at UGM. The research collective is spearheaded by Rina Putri Cahyati, an undergraduate student from the Faculty of Medicine, Public Health, and Nursing, specifically majoring in Nursing Science. Rina united with four other talented students representing diverse disciplines across the university to combine clinical understanding with hardware and software engineering. The entire project operates under the academic mentorship of Ir. Ma’un Budiyanto, S.T., M.T., IPU, an experienced faculty advisor.

Engineering and Design Phase

The multidisciplinary team spent months refining the physical ergonomics of the footwear. They needed to ensure that electronic components—such as microcontrollers, pressure sensors, and wireless transmission modules—were seamlessly embedded without compromising the structural integrity or comfort of the sandal. Simultaneously, software developers built the mobile dashboard and risk-stratification algorithms.

Ethical Clearance and Clinical Testing (Mid-2026)

Prior to human trials, the team subjected the prototype to rigorous safety evaluations. The research protocol successfully secured ethical clearance from the Medical and Health Research Ethics Committee (MHREC) of the Faculty of Medicine, Public Health, and Nursing at UGM (Komite Etik FK-KMK UGM).

With official ethical approval in hand, the team moved to field trials at the Korpagama Clinic in Yogyakarta. The testing phase involved clinically diagnosed type 2 diabetes patients. During the trials, participants first underwent baseline foot sensitivity screenings. They were then asked to walk while wearing the Glucowrap for a standardized 15-minute testing window, allowing the sensors to map pressure and thermal dynamics accurately. Afterward, participants completed qualitative evaluations regarding the comfort of the footwear and the usability of the mobile application.

3. Supporting Data: The Burden of Diabetic Neuropathy

To fully contextualize the importance of the UGM team’s innovation, one must examine the staggering epidemiological data surrounding diabetes and its podiatric complications.

According to the International Diabetes Federation (IDF) and national health statistics in Indonesia, the prevalence of diabetes continues to climb upward, positioning the nation among the top global epicenters of the disease. Type 2 diabetes accounts for over 90% of all diabetes cases.

• The Neuropathy Epidemic: Clinical studies indicate that roughly 50% of all individuals with long-standing diabetes will eventually develop peripheral neuropathy.
• The Amputation Risk: Diabetic foot ulcers precede approximately 85% of all diabetes-related lower-extremity amputations. In developing nations, delayed presentation of foot ulcers often converts a treatable lesion into a systemic infection requiring surgical removal of the limb.
• Economic and Psychological Toll: The cost of managing diabetic foot complications—ranging from long-term wound care dressings and hyperbaric oxygen therapy to surgical debridement and prosthetic rehabilitation—places an immense financial burden on healthcare systems and families. Furthermore, chronic wounds severely degrade the patient’s quality of life, leading to mobility loss, chronic pain, depression, and social isolation.

By introducing a preventative tool that catches micro-traumas before they manifest as open wounds, the Glucowrap directly targets the primary pipeline of diabetic amputations.

4. Official Responses and Perspectives

The unveiling of the Glucowrap has drawn widespread praise from the academic community, medical professionals, and the student innovators themselves.

The Student Lead’s Perspective

Speaking to the official UGM public relations portal, project leader Rina Putri Cahyati emphasized the clinical rationale behind their invention:

"Peripheral neuropathy systematically degrades sensory feedback in the lower extremities, meaning patients frequently remain entirely oblivious to localized pressure concentrations, abrasive friction, or dangerous thermal shifts on their skin," Rina explained.

"If these subtle warning signs are overlooked and left untreated, they inevitably cascade into deep-seated tissue damage and chronic ulcerations. We built Glucowrap to give these patients an artificial nervous system for their feet."

Despite the enthusiastic reception and successful preliminary trials, Rina remains scientifically grounded regarding the current capabilities of the device:

"Glucowrap remains an active work-in-progress and is presently undergoing continuous research and development. We want to emphasize transparently that this device is not intended to replace professional medical examinations, diagnoses, or treatments administered by physicians. Rather, it has been meticulously engineered to function as an advanced supportive monitoring tool to aid patients in daily self-care."

Institutional and Faculty Support

The guidance of Ir. Ma’un Budiyanto, S.T., M.T., IPU, proved instrumental in navigating the complex intersection of biomedical engineering and consumer product design. Faculty leadership at UGM has consistently highlighted the Glucowrap project as a shining example of translational research—where classroom theories are transformed into tangible solutions that directly address pressing societal challenges in public health.

5. Implications and Future Outlook

The development of the Glucowrap carries profound implications for the future of chronic disease management, preventative medicine, and wearable health technology in Indonesia and beyond.

Paradigm Shift from Reactive to Preventative Care

Traditional diabetes management heavily emphasizes glycemic control, dietary modifications, and pharmacological interventions. Foot care is frequently reactive—patients are instructed to inspect their feet daily using mirrors or rely on periodic clinical check-ups. Unfortunately, visual inspections often fail to detect internal tissue stress, sub-surface inflammation, or subtle temperature anomalies.

The Glucowrap shifts this paradigm to a proactive, continuous monitoring model. By transforming footwear into an intelligent diagnostic node, patients receive immediate feedback, enabling them to rest the affected foot, adjust their footwear, or consult a podiatrist before skin breakdown occurs.

Commercialization and Accessibility Goals

Looking ahead, the UGM student team and their faculty mentors harbor ambitious long-term aspirations. Their ultimate objective is to refine the hardware architecture and software algorithms until Glucowrap can transition into a fully realized, standalone medical device.

To achieve widespread clinical impact, future development phases will focus heavily on:

1. Cost Optimization: Ensuring that manufacturing expenses remain low so that the final product is financially accessible to lower- and middle-income socioeconomic groups who often bear the highest burden of diabetic complications.
2. Miniaturization and Durability: Enhancing the water-resistance and battery life of the internal electronics to withstand the rigors of daily tropical usage.
3. Clinical Integration: Collaborating with endocrinologists, general practitioners, and hospitals to integrate Glucowrap data outputs directly into electronic medical record (EMR) systems, allowing doctors to track long-term ambulatory metrics during routine check-ups.

Conclusion

As global healthcare systems grapple with aging populations and rising chronic disease burdens, innovations like the UGM Glucowrap represent a beacon of hope. By fusing compassionate clinical insight with modern sensor technology and materials science, these young Indonesian researchers have not only designed a smart sandal—they have paved a safer, more stable pathway forward for millions living in the shadow of diabetes.